Navigation Links
Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:5/26/2008

REINACH, Switzerland, May 26 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) today announced the enrolment of the first patients into the Phase II "intravenous-to-oral" switch trial with oral iclaprim in complicated Skin and Skin Structure Infections (cSSSI). Enrolment remains on track for completion in 2008.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with a full course of intravenous (i.v.) treatment with vancomycin in the treatment of cSSSI. The primary endpoint will be the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcomes as well as safety and tolerability.

This Phase II trial is designed as a multi-centre, double-blind, double-dummy comparative study. Patients suffering from cSSSI receive i.v. vancomycin for the first two days of treatment and are then randomised to either continue to receive i.v. vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients will be randomised for this study.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Among the hospital anti-MRSA drugs that are currently in filing or late-stage development, only iclaprim shows oral bioavailability allowing clinical development and consequently offers the potential for intravenous-to-oral switch therapy. We consider the oral switch therapy to be an important option addressing an increasing therapeutic need. It allows patients to be sent home earlier, thereby increasing patient comfort, reducing the risk of contracting additional infections and lowering costs for the healthcare system. We feel the oral switch therapy could add significant potential to the intravenous formulation."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and dev
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... The following is being released by ... The Green Park Collaborative (GPC) will bring together ... medical device and pharmaceutical companies, as well as ... 2015 at its first ever workshop on the ... Participants will discuss study designs to evaluate weight ...
(Date:10/17/2014)... NORWALK, Conn. , Oct. 17, 2014  UBM ... leading online community for endocrinologists and other clinicians who ... offers comprehensive coverage on effective use of insulin ... will eventually require insulin replacement therapy – ... up for the progressive decline in the function of ...
(Date:10/17/2014)... 2014  Ameritox SM , the nation,s leader in ... Thomas Smith , M.D., as Chief Medical Officer. In ... scientific resources for healthcare providers, patients and managed care ... at a variety of healthcare companies that have provided ... and behavioral health sides of Ameritox,s business. He most ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2
... Generex Biotechnology Corporation ( www.generex.com ) (OTCBB: ... President & Chief Executive Officer, and Dr. Eric ... Antigen Express, Inc. ( www.antigenexpress.com ) will make ... 13th Annual Healthcare Conference.  The presentation will take ...
... CITY, Calif., Sept. 7, 2011 Codexis, Inc. ... the company will be participating in the following ... ConferenceDate: Thursday, September 15, 2011 (Company presentation)Time: 8:00 ... of Financial Planning & Analysis A webcast and ...
Cached Medicine Technology:Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 3
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 Women’s ... Specialists in Obstetrics & Gynecology of Columbus, Inc., A ... women’s healthcare services to more than 100,000 patients annually. ... though all ages and stages of a women’s life. ... office locations in Westerville and Dublin. , Dr. ...
(Date:10/20/2014)... hc1.com today announced the launch ... that enables healthcare organizations of all sizes to ... relationship management (“CRM”) solution. , Designed from the ... the healthcare industry, the hc1 Healthcare Relationship Cloud™ ... by combining healthcare CRM, HIPAA-compliant collaboration, and real-time ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 JZ ... expertise, nutritional coaching, corporate wellness programming, authorship, international lecturing ... is excited to announce the release of the JZ ... After many years of coaching thousands of individuals on ... tracking app that does not require calorie counting or ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned ... top-of-the-line absorbent products. The company has recently made ... brand, Tranquility® Premium Protection absorbent products. The company ... its packaging a new look, and is currently working ... the public. , The new website, developed with Thread ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... , , CHICAGO, Sept. ... by House Majority Leader Steny Hoyer (D-MD) - for recognizing the ... the overall health care reform bill currently under consideration. Over ... Democrats and Republicans across the country talking with constituents at town ...
... , , , ... Supermarkets are helping customers stay healthy and well by once ... period will start September 17 and run through November 1 ... doctor-administered vaccines. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20030421/STATERLOGO ...
... , , , JACKSONVILLE, ... taking place Friday, Sept. 11, 2009, Wounded Warrior Project (WWP) and ... revenues generated from global trades made on that day. , , ... was created while Cantor Fitzgerald rebuilt following the World Trade Center attacks ...
... , , FARMINGDALE, N.Y., ... a developer of minimally invasive ultrasonic medical device technology, which ... worldwide for other acute health conditions, today announced the restructuring ... business units have been created; one for sales and service ...
... COLO Research published in the September 2009 issue of ... an individual,s quality of life prior to treatment can help ... cell lung cancer (NSCLC). For those with advanced stage ... months, with approximately one-third of patients surviving past the one ...
... are developing computer models to comb through thousands of ... claims data to automatically classify them based on specific ... the most important causes of injuries so that efforts ... in society," said Mark Lehto, an associate professor in ...
Cached Medicine News:Health News:Statement from the American College of Surgeons Regarding Growing Democrat Support for Medical Liability Reform to be Included in Health Care Reform 2Health News:Stater Bros. Helps Customers Fight the Flu 2Health News:Wounded Warrior Project to Participate in BGC Partners Annual Charity Day 2Health News:Misonix Restructures and Expands Sales Organization in Europe 2Health News:Misonix Restructures and Expands Sales Organization in Europe 3Health News:Misonix Restructures and Expands Sales Organization in Europe 4Health News:New computer models aim to classify, help reduce injury accidents 2
ENA Screen EIA Auto-Immune Markers 012-MDKES1 Extractable Nuclear Antigens...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
... can be viewed immediately, making procedures more efficient. ... the images are digital, they can be used ... electronic filing. The CR-DGi combines the power ... use. It's the latest advance from Canon, the ...
...
Medicine Products: